Wolfe's $9.2 Billion Intismeran Call Snaps Moderna's Post-Readout Unwind

The Most Bearish Desk on the Street Blinked

Moderna closed Tuesday, August 25 at $158.83, up 14.36% on roughly 50.0 million shares, with a session range of $140.50 to $160.00. The proximate cause was a rating change from the desk that had been most negative on the name: Wolfe Research's Alexandria Hammond moved MRNA to Peer Perform from Underperform, modeling $9.2 billion in unadjusted peak sales for intismeran autogene across four indications — adjuvant melanoma, renal cell carcinoma, muscle-invasive bladder cancer and non-small cell lung cancer.

Sit with that number for a second, because the framing matters more than the headline. That $9.2 billion is gross and pre-split. Merck paid $250 million in 2022 to exercise its option into a 50/50 share of development costs and profits, so the Moderna half is closer to $4.6 billion of peak revenue — against a $63.41 billion market cap. And that is the bull-adjacent case from an analyst who upgraded all the way to *neutral*.

The day before, Barclays' Eliana Merle raised her target to $125 from $48 while keeping Equal Weight, writing that the stock already assigns significant credit to intismeran across tumors. BofA's Alec Stranahan went to Hold from Sell with a $170 target on August 20, calling the data a watershed moment. Three of the loudest revisions on this move are upgrades to *hold*. Consensus across 23 analysts is still Hold at an average target of $99.82 — about 37% below the tape.

The Trade Is the Unwind, Not the Readout

The real event was six days earlier. On August 19, Merck and Moderna announced that INTerpath-001 met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival in 1,137 patients with completely resected stage IIB–IV cutaneous melanoma, randomized 2:1 to intismeran plus KEYTRUDA versus KEYTRUDA alone. It is the first late-stage win for an mRNA cancer therapy. The stock closed +176.97% at $174.38, its largest single-day gain on record.

The mechanics underneath were as important as the science. MRNA went into that print with roughly 13.5% of its free float short — one of the most-shorted large caps in the market. S3 Partners put the one-day damage at about $5.5 billion in mark-to-market losses for bears. Binary catalyst, crowded short, no exit.

Then the giveback. Moderna fell as much as 25% on August 20 to around $129, erasing $18 billion, traded $133.32 on August 21, and lost another 5.13% on August 24. Tuesday's 14.36% recovered less than half of the drawdown from the August 19 close. That is the honest shape of this move: a squeeze, a de-squeeze, and a partial retrace on sell-side housekeeping.

One detail the price action is glossing over — the companies did not disclose a Phase 3 hazard ratio. The press release cites the earlier Phase 2b KEYNOTE-942 figures (a 49% RFS reduction, HR 0.51). The actual size of the Phase 3 effect is still unpublished, pending presentation at an upcoming medical meeting.

What the Perp Priced That the Tape Didn't

On Hyperliquid, the trade.xyz-deployed MRNA perp is up 15.26% over 22 hours to $157.50, a wider move than the 14.36% cash session. Back out the percentage and the window's base sits near $136.65 — roughly 2.7% below the Nasdaq session low of $140.50. The perp marked lows the cash market never printed, because it was open while the Nasdaq was not.

That is the structural difference on a HIP-3 equity perp, and on this name it cuts both ways. MRNA has produced a +177% day and a −25% day inside a single week. Holding the perp through the Nasdaq's closed hours means carrying that gap risk with no cash reference and a thinner book: $17.3 million of 24-hour volume on this market, against roughly 50 million shares traded in the underlying. Up to 10x leverage is available, which is a fast way to get liquidated on an overnight repricing that no one is around to arbitrage.

What Actually Resolves This

Three things, in order of how much they should move the price. First, the full INTerpath-001 dataset at a medical meeting — hazard ratios, subgroup performance, and the safety profile of nine doses of a personalized neoantigen therapy stacked on a checkpoint inhibitor. Second, regulatory engagement; the companies say they will discuss filings, but no submission timeline exists yet, and Moderna's 2026 flu-vaccine path went Refusal-to-File in February before approval in August. Regulatory risk on this name does not resolve cleanly. Third, overall survival, which remains immature.

Underneath all of it, the business has not changed. Trailing twelve-month revenue is $2.23 billion and shrinking 27.6%, against a $3.15 billion net loss and EPS of −$8.01. The stock is up roughly 392% year to date off a 52-week low of $22.28. What August 19 bought was optionality on an oncology franchise that generates no revenue today and splits its economics with Merck when it does. Whether $63 billion is the right price for that option is the entire argument, and the analysts pounding the table on the science are still, almost uniformly, rating it Hold.